Saxagliptin, a type 2 diabetes drug, has been linked to potential heart failure. According to a recent update announced by the United States Food and Drug Administration (FDA), type 2 diabetes drugs containing saxagliptin and alogliptin may be a reason for increased risk of heart failure. The risks are amplified in users who already experience heart or kidney disease. The FDA has required the drug to add new warnings on the labels regarding the associated risks.
The drugs containing saxagliptin and alogliptin include Oseni, Kombiglyze XR, Onglyza, Kazano, and Nesina.
Two trials in which two groups of patients were given saxagliptin and placebos showed that the patients who took the saxagliptin, 3.5% of them were hospitalized for heart failure. In comparison, 2.8% of the patients who took the placebo had the same issue. This study was evaluated by the FDA to show the increased risk of heart failure in users who have taken drugs containing saxagliptin.
It is important for drug manufacturers to make sure their drugs are safe for consumer use. If they are aware of potential side effects, they must make consumers aware of them using warning labels. When a manufacturer fails to protect consumers, they can be considered negligent and should be held accountable for their actions. Any patient who suffers serious heart failure as a result of saxagliptin-containing drugs should be able to obtain justice for the wrongs done to them.
Our Cleveland dangerous drug attorneys at Spangenberg Shibley & Liber LLP believe that victims of dangerous drugs deserve compensation for the damages they have sustained. If you or someone you love has suffered heart failure after taking a drug containing saxagliptin, you should contact our firm as soon as possible. We know how difficult this can be for you to endure. It is our goal to represent you and help you seek the results you desire.
